Spin-off Partnerships IRB Barcelona has multiple spin-off companies (e.g., Inbiomotion, Nuage, Nostrum Biodiscovery, Ona Therapeutics, Gate2brain, HelixAI) actively translating research into clinic and market. This indicates a strong openness to collaboration, licensing, and joint development opportunities across biotech, pharma, and digital health sectors.

AI Molecule Design Recent advances include a phenotypic generative AI system and a computational framework for designing molecules with cell-type selective activity. Target this for drug discovery partnerships, contract research, and AI-enabled R&D services that leverage IRB’s cutting-edge computational biology capabilities.

Clinical Translation With a track record of moving findings toward patients and six active spin-offs, IRB Barcelona seeks to accelerate translation from bench to clinic. Position value propositions around translational services, early-access programs, and royalty-based or milestone-driven collaborations.

Strategic Funding & Prestige As a Severo Ochoa Centre of Excellence and a member of the Barcelona Institute of Science and Technology, IRB Barcelona carries credibility and access to basic science networks. This can facilitate co-funding, joint grant applications, and government-backed partnerships that de-risk collaborative pursuits.

Broad Research Focus Core domains include Cancer Science, Aging & Metabolism, and Mechanisms of Disease, complemented by AI and computational biology initiatives. This breadth supports multi-area collaboration leads across pharma, biotech, and academia, enabling cross-disciplinary opportunities for sponsored research, technology licensing, and capability-building engagements.